



Developing therapeutic treatment for **Neuropathic Pain** with a novel, synthetic **non-opioid** small molecule (CB2 receptor agonist)

**TBD Therapeutics Inc.**

Is a USA company established  
by the Co-Founders :

Esther Farkash,  
Tel-Aviv, Israel  
972-544674641

Merav Krasner,  
NJ, USA  
908-300-7910

[www.tbdtherapeutics.com](http://www.tbdtherapeutics.com)  
[info@tbdtherapeutics.com](mailto:info@tbdtherapeutics.com)

# Table of Content



- Introduction Slide 3
- The Technology / IP Slides 4-5
- Neuropathic Pain- Main causes Slide 6
- Neuropathic Pain- The Solution Slide 7
- The Team Slides 8-10
- Development Milestones Slides 11-12
- Investment Request to Fund Core Activities Slide 13



# Introduction



## **TBD Therapeutics Inc. is an early-stage start-up planning:**

- To address the serious unmet need in treating **Neuropathic Pain** with a safe, efficacious, non-narcotic pharmaceutical drug.
- There is an urgent need to find alternative safer treatments to fight the opioid painkillers crisis. Opioids are the deadliest drug type.
- The active ingredient is a proprietary novel synthetic CB2 receptor agonist.

## **Neuropathic Pain is an unmet need**

- A debilitating chronic pain common in many health conditions at any age.
- Better treatment will improve health, quality of life of patients & their families, leading to much greater Longevity.

## **The global Neuropathic Pain market**

- The global Neuropathic Pain market was valued at 7.37 billion in 2023. The market is projected to grow from 7.79 billion in 2024 to 14.05 billion USD in 2032 exhibiting a CAGR of 7.7%. North America dominated the neuropathic pain market with a market share of 49.93% in 2023 [Fortune Business Insights Nov.2024]

# Our Technology/IP: HU-910



- **A novel proprietary camphor based synthetic small molecule**
- **HU-910** possesses analgesic, anti-inflammatory and immuno-protective proven properties.
- **The molecule activates a sequence of processes**, via initial attachment to the CB2 receptors throughout the body's Endo-Cannabinoid System. Resulting in, secretion of natural intrinsic pain & inflammation modulation compounds in the body that can prevent or reduce development of pain and inflammation.
- **It is a safe, efficacious, non-psychoactive** (not a narcotic) CB2 receptor agonist with high affinity to CB2 receptors, high potency and high level of penetration into injured tissues.
- **HU-910** demonstrated equipotent analgesic effect as morphine and ibuprofen in chemotherapy-induced neuropathic pain model in mice.  
Chemotherapy-induced neuropathic pain is one of the many types of chronic neuropathic pain.





# Our Technology/IP:HU-910



- **We have signed a Licensing Agreement** -The Hebrew University in Jerusalem (the owner of the patent) granting us exclusive rights to develop and commercialize HU-910.
- **Patent – “New Chemical Entity/Composition of Matter”** comprise of a wide range of relevant therapeutic indications, was registered and a patent was granted to Hebrew University, in key strategic markets including the USA, Europe and RoW (rest of world).
- **IP strategy: Protect, Expand & Strengthen the initial patent, including :**
  - Development of a unique delivery system- per the chosen Route of Administration.
  - Key new findings in specific therapeutic areas, following the initial core Neuropathic Pain indication.

# Neuropathic Pain–Main Causes

- **Physical Injury & Trauma**
- **Musculoskeletal health conditions**
- **Auto-Immune Diseases**
- **Cancer**
- **Growing Elderly Population**
- **Neurological Diseases**
- **Diabetes**
- **Central Nervous System Disorders**
- **Women related conditions**
- **Alcoholism**





# Neuropathic Pain – The Solution;

HU-910 solves this significant unmet need



## **As an efficacious, safe, non-narcotic drug, HU-910 will:**

- Improve patients' compliance with continuous treatment
- Improve patients' daily quality of life
- Improve patients' ability to work and their economical situation
- Improve patient's family members' quality of life
- Reduce side effects in patients who have chronic pain with comorbidities
- Patients are less likely to develop tolerance with chronic use
- Keep patients away from all types of medical facilities, from consuming more and more medications- Reducing drastically healthcare system costs.
- To Conclude- Better treatment will improve health , quality of life and vitality, leading to much greater LONGEVITY.



# THE TEAM

## Co-Founders & Directors

**Esther Farkash**



**Merav Krasner**



**The Team at this initial early stage. More team members will be added.**

**Strategic Selection of a “Power-House” with the knowledge & skill set to fully execute the development plan**

- **Pharmaceutical Regulatory Expert.**
- School of Pharmacy graduate with 25+ years experience in Regulatory Affairs of drug development & licensing processes at global leading pharmaceutical companies.
- Vast experience working on Neurology and Psychiatry drugs, including fentanyl and topiramate that are directly relevant for the neuropathic pain indication.
- **Marketing & Commercialization Strategy Expert.**
- BSc in life Science, with 25+ years of commercial experience working in the global pharmaceutical, diagnostics and medical devices industries.
- Strong product development & marketing experience in the CNS, Oncology and Wound Care space.



# THE TEAM



## Prof. Doron Steinberg



### Scientific Advisor

Prof. Doron Steinberg is The Head of the BIOFILM Research Laboratory and a researcher at The Multidisciplinary Center for Cannabinoids research at The Hebrew University in Jerusalem, Israel.

- Prof. Steinberg worked with the molecule designer Prof. Mechoulam on different research projects concerning Endo-Cannabinoids and Cannabinoids.
- Prof. Steinberg has many patents of which one has evolved into a commercial product- PerioChip, a prescription medicine.

## Mrs. Techiya Toaff



### Clinical Regulatory & Strategic Expert

- 20+ years experience in clinical research, regulatory and trials in the pharmaceutical industry.
- Worked at the FDA as regulatory project manager.

# THE TEAM

Service providers &  
Consultants



**ProPharma Group, Washington D.C.**

**Regulatory Strategic  
Plans**

**Pre-Clinical Expert**

**IND & NDA  
preparation**

- The leading global single-source independent provider of regulatory services for clients in the pharmaceutical, biotechnology and medical devices industries.
- Specializing in regulatory & compliance consulting throughout the full product lifecycle working with the FDA, EMA, and other national agencies throughout Europe.



# HU-910 Development Completed Milestones



- **Design & Development:** of the molecule HU-910 by Prof. Mechoulam.
- **Patent Granted:** The Hebrew University, Jerusalem, Israel.
- **TBD Therapeutics Inc.** signed an exclusive licensing agreement with the university.
- **Initial Proof of Concept:** Pre-clinical study at the university laboratories with HU-910 demonstrated equipotent analgesic effect as morphine and ibuprofen in chemotherapy-induced neuropathic pain (as one type of neuropathic pain).
- **Pre-Clinical Regulatory Strategic Plan:**  
Prepared, ready for the start of the pre clinical studies.  
CROs to conduct the preclinical studies were identified and contacted.
- **Funding** of this project – till now > \$150,000 were invested privately by the Co-founders.

# HU-910 Development Planned Milestones



- **IND enabeling Pre-Clinical Studies:**

Efficacy and Safety studies to obtain evidence-based data for FDA pre-IND discussions and IND preparations towards fast-track process. 2025-2026

- **Fundraising for conducting preclinical efficacy studies:**

\$ 2-3M - 2025-2006.

- **Go To Market/Channel strategy:**

1. Identify strategic partners for full development & commercialization for the therapeutic indication Neuropathic Pain.
2. Exit options
3. Continue development of more therapeutic indications per patent.



# Investment Request to Fund Core Activities



## **In order to reach key milestones, we will require:**

\$2-3M to complete the IND enabling preclinical Efficacy Studies, and prepare the IND and FDA discussions for a fast-track process.

**TBD Therapeutics would like to pursue a SAFE (Simple Agreement For Future Equity) investment agreement offering investors future equity in the company in exchange for their investment. We will consider other types of investments.**

# Thank You

